izpis_h1_title_alt

Lipidation of NOD2 agonists with adamantane and stearoyl moieties differentially regulates their In vivo adjuvant activity
ID Guzelj, Samo (Author), ID Šišić, Marcela (Author), ID Janež, Špela (Author), ID Frkanec, Leo (Author), ID Frkanec, Ruža (Author), ID Jakopin, Žiga (Author)

.pdfPDF - Presentation file, Download (980,38 KB)
MD5: CAA8038FCF6A548E07255B70BFDF4D36
URLURL - Source URL, Visit https://www.mdpi.com/1999-4923/14/12/2755 This link opens in a new window

Abstract
NOD2 is an innate immune receptor that constitutes an important target for the development of small molecule immunopotentiators with great potential to be used as vaccine adjuvants. We report here the results of an in vivo study of the adjuvant properties of a desmuramylpeptide NOD2 agonist SG29 and its lipidated analogs featuring an adamantyl moiety or a stearoyl group. These compounds have been synthesized, incorporated into liposomes, and evaluated for their in vivo adjuvant activity. The characterization of liposome formulations of examined compounds revealed that their size increased in comparison to that of empty liposomes. The introduction of a stearoyl or an adamantane lipophilic anchor into the structure of SG29, to produce SG115 and ZSB63, respectively, substantially improved the in vivo adjuvant activity. Of note, the attachment of the stearoyl moiety produced a Th2-biased immune response, while the incorporation of the adamantyl moiety greatly enhanced the production of total IgG but mostly augmented the production of IgG2a antibodies, which indicated a shift toward a Th1 immune response. The identified bona fide capacity of ZSB63 to initiate a cellular immune response thus highlights its untapped potential as an alternative vaccine adjuvant.

Language:English
Keywords:NOD2 agonist, vaccine adjuvant, adamantane, immunopotentiators, desmuramylpeptides
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2022
Number of pages:9 str.
Numbering:Vol. 14, iss. 12, art. 2755
PID:20.500.12556/RUL-143240 This link opens in a new window
UDC:615.4:54:616-097
ISSN on article:1999-4923
DOI:10.3390/pharmaceutics14122755 This link opens in a new window
COBISS.SI-ID:133033219 This link opens in a new window
Publication date in RUL:09.12.2022
Views:631
Downloads:91
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Pharmaceutics
Shortened title:Pharmaceutics
Publisher:MDPI
ISSN:1999-4923
COBISS.SI-ID:517949977 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:agonisti NOD2, adjuvans za cepivo, adamantan, imunopotenciatorji, desmuramilpeptidi

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0208-2022
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARRS - Slovenian Research Agency
Project number:P1-0420-2022
Name:Napredna imunološka zdravila in celični pristopi v farmaciji

Funder:ARRS - Slovenian Research Agency
Project number:J3-2517-2020
Name:Razvoj himernih multiplih agonistov receptorjev prirojene imunosti kot učinkovitih adjuvansov za cepiva

Funder:ARRS - Slovenian Research Agency
Project number:J3-9256-2018
Name:Razvoj agonistov receptorja NOD2 ter dualnih NOD2/TLR7 agonističnih konjugatov kot novih adjuvansov za cepiva

Funder:HRZZ - Croatian Science Foundation
Project number:IP-2018-01-6910
Name:Sinteza supramolekulskih samo-udruženih nanostruktura za izgradnju naprednih funkcionalnih materijala

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back